<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Teduglutide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08900</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Teduglutide is a glucagon-like peptide-2 (<span class="caps">GLP</span>-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant <span class="caps">DNA</span> technology. Teduglutide differs from <span class="caps">GLP</span>-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous <span class="caps">GLP</span>-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. <span class="caps">FDA</span> approved on December 21, 2012.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>164</sub>H<sub>252</sub>N<sub>44</sub>O<sub>55</sub>S</td></tr><tr><th>Protein average weight</th><td>3752 Da </td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;Protein sequence for teduglutide
HGDGSFSDEMNTILDNLAARDFINWLIQTKITD</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB08900/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>ALX-0600</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Teduglutide [rDNA origin]</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Teduglutide Recombinant</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Gattex </td><td>NPS Pharmaceuticals</td></tr><tr><td>Revestive</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>197922-42-2</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support. </td></tr><tr><th>Pharmacodynamics</th><td>An enhancement of gastrointestinal fluid absorption (750-1000 mL/day) was observed following daily administrations of teduglutide. An increase in villus height and crypt depth of the intestinal mucosa was also noted. A decrease in fecal weight has also been observed. Teduglutide does not prolong the QTc interval. </td></tr><tr><th>Mechanism of action</th><td>Teduglutide is an analog of naturally occurring human glucagon-like peptide-2 (GLP-2), a peptide secreted by L-cells of the distal intestine in response to meals. GLP-2 increases intestinal and portal blood flow and inhibit gastric acid secretion. Teduglutide binds to the glucagon-like peptide-2 receptors located in enteroendocrine cells, subepithelial myofibroblasts and enteric neurons of the submucosal and myenteric plexus. This causes the release of insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF). These growth factors may contribute to the increase in crypt cell growth and surface area of the gastric mucosa. Ultimately, absorption through the intestine is enhanced. </td></tr><tr><th>Absorption</th><td>The pharmacokinetic profile of teduglutide (when administered subcutaneously) is described by a one-compartment model with first order absorption in the abdomen, arm, and thigh. With escalating doses, teduglutide demonstrates linear pharmacokinetics. 
Absolute bioavailability, SubQ = 88%;
Tmax, SubQ = 3-5 hours;  
Cmax, 0.05 mg/kg SubQ, SBS patients = 36 ng/mL; 
AUC, 0.05 mg/kg SubQ, SBS patients = 0.15 &#181;g&#8226;hr/mL;
Teduglutide does not accumulate following multiple subcutaneous administrations. </td></tr><tr><th>Volume of distribution</th><td><p>Vd, healthy subjects = 103 mL/kg</p></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Although a formal investigation has not been conducted, it is expected because teduglutide is a peptide-based drug, it will be degraded into smaller peptides and amino acids via catabolic pathways. The cytochrome P450 enzyme system is not involved in the metabolism of this drug. </p></td></tr><tr><th>Route of elimination</th><td>Urine </td></tr><tr><th>Half life</th><td>Terminal half-life, healthy subjects = 2 hours;
Terminal half-life, SBS patients = 1.3 hours </td></tr><tr><th>Clearance</th><td><p>Plasma clearance, healthy subjects = 123 mL/hr/kg;<br>
This value indicates that teduglutide is primarily cleared by the kidney.</p></td></tr><tr><th>Toxicity</th><td>The most common adverse reactions (&#8805; 10%) across all studies with GATTEX are abdominal pain, injection site reactions, nausea, headaches, abdominal distension, upper respiratory tract infection. In addition, vomiting and fluid overload were reported in the SBS studies (1 and 3) at rates &#8805; 10%. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, for solution</td><td>Subcutaneous</td><td>5 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5789379</td><td>2012-12-21</td><td>2015-04-14</td></tr><tr><td>United States</td><td>7056886</td><td>2012-12-21</td><td>2022-09-18</td></tr><tr><td>United States</td><td>7847061</td><td>2012-12-21</td><td>2025-11-01</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Burness CB, McCormack PL: Teduglutide: A Review of its Use in the Treatment of Patients with Short Bowel Syndrome. Drugs. 2013 Jun 1. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23729002">Pubmed</a></li>
	<li>Semrad CE: The Long Road to a New Short-Bowel Therapy: Teduglutide for Clinical Use. Clin Gastroenterol Hepatol. 2013 Apr 13. pii: S1542-3565(13)00471-0. doi: 10.1016/j.cgh.2013.03.030. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23591284">Pubmed</a></li>
	<li>Jeppesen PB: Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therap Adv Gastroenterol. 2012 May;5(3):159-71. doi: 10.1177/1756283X11436318. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22570676">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/gattex-drug.htm" target="_blank">http://www.rxlist.com/gattex-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/mtm/teduglutide.html" target="_blank">http://www.drugs.com/mtm/teduglutide.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Teduglutide" target="_blank">Teduglutide <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>A16AX08<ul class="atc-drug-tree"><li><a href="/atc/A#A">A &#8212; ALIMENTARY TRACT AND METABOLISM</a></li><li><a href="/atc/A16#A16">A16 &#8212; OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</a></li><li><a href="/atc/A16A#A16A">A16A &#8212; OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</a></li><li><a href="/atc/A16AX#A16AX">A16AX &#8212; Various alimentary tract and metabolism products</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>56:92</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB08900.pdf?1370497501">show</a>(410 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>